Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension

References

• WalkerWNeatonJCutlerJRNCohenJRenal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research GroupJAMA199226821308530911433739
   PubMed Web of Science ®Google Scholar
• MacMahonSPetoRCollinsRBlood pressure, stroke, and coronary heart disease : Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasLancet199033586927657741969518
   PubMed Web of Science ®Google Scholar
• KannelWBBlood pressure as a cardiovascular risk factor: prevention and treatmentJAMA1996275157115768622248
   PubMed Web of Science ®Google Scholar
• KearneyPWheltonMReynoldsKMuntnerPWheltonPHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• OngKLCheungBMYManYBLauCPLamKSLPrevalence, awareness, treatment, and control of hypertension among united states adults 1999–2004Hypertension2007491697517159087
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• FagardREpidemiology of hypertension in the elderlyAm J Geriatr Cardiol2002111232811773712
   PubMedGoogle Scholar
• DyerAStamlerJShekelleRSchoenbergerJFarinaroEHypertension in the elderlyMed Clin North Am1977613513529857105
   PubMed Web of Science ®Google Scholar
• SkoogILernfeltBLandahlS15-year longitudinal study of blood pressure and dementiaLancet19963479009114111458609748
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRPSCollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• FranklinSSLarsonMGKhanSADoes the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart StudyCirculation200110391245124911238268
   PubMed Web of Science ®Google Scholar
• BenetosAZureikMMorcetJA decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in menJ Am Coll Cardiol200035367368010716470
   PubMed Web of Science ®Google Scholar
• MeaumeSBenetosAHenryOFRudnichiASafarMEAortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of ageArterioscler Thromb Vasc Biol200121122046205011742883
   PubMed Web of Science ®Google Scholar
• Sutton-TyrrellKNajjarSSBoudreauRMElevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adultsCirculation2005111253384339015967850
   PubMed Web of Science ®Google Scholar
• US Census BureauPersons 65 Years Old and Over-Characteristics by Sex:1980 to 2000Washington DCStatistics Bureau2001
   Google Scholar
• FranklinSSJacobsMJWongNDL’ItalienGJLapuertaPPredominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives: Analysis Based on National Health and Nutrition Examination Survey (NHANES) IIIHypertension200137386987411244010
   PubMed Web of Science ®Google Scholar
• KostisJDavisBCutlerJPrevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research GroupJAMA19972782122169218667
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research GroupPrevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)JAMA1991265325532642046107
   PubMed Web of Science ®Google Scholar
• StaessenJAThijsLFagardRPredicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertensionJAMA1999282653954610450715
   PubMed Web of Science ®Google Scholar
• DanserABatenburgWvan EschJProrenin and the (pro)renin receptor-an updateNephrol Dial Transplant20072251288129217259648
   PubMed Web of Science ®Google Scholar
• GradmanAHKadRRenin inhibition in hypertensionJ Am Coll Cardiol20085151952818237679
   PubMed Web of Science ®Google Scholar
• NguyenGThe (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathologyCurr Opin Nephrol Hypertens20071612913317293688
   PubMed Web of Science ®Google Scholar
• GueyffierFBulpittCBoisselJ-PAntihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trialsLancet1999353915579379610459960
   PubMed Web of Science ®Google Scholar
• BeckettNSPetersRFletcherAETreatment of hypertension in patients 80 years of age or olderN Engl J Med2008358181887189818378519
   PubMed Web of Science ®Google Scholar
• European Stroke Initiative Executive CommitteeEUSI Writing Committee OTLanghornePDienerHCHennericiMEuropean Stroke Initiative Recommendations for Stroke Management-update 2003Cerebrovasc Dis200316431133714584488
   PubMed Web of Science ®Google Scholar
• International Society of Hypertension Writing GroupInternational Society of Hypertension (ISH): Statement on blood pressure lowering and stroke preventionJ Hypertens20032165165312658005
   PubMed Web of Science ®Google Scholar
• AlbertsMUpdate on the treatment and prevention of ischaemic strokeCurr Med Res Opin200319543844113678483
   PubMed Web of Science ®Google Scholar
• Authors/Task Force MManciaGDe BackerGGuidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J200728121462153617562668
   PubMed Web of Science ®Google Scholar
• DahlöfBHanssonLLindholmLHSchersténBEkbomTWesterPOMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)Lancet19913388778128112851682683
   PubMed Web of Science ®Google Scholar
• GueyffierFBoutitieFBoisselJPEffect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trialsAnn Intern Med1997126107617679148648
   PubMed Web of Science ®Google Scholar
• StaessenJAFagardRThijsLRandomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionLancet199735090807577649297994
   PubMed Web of Science ®Google Scholar
• LiuLWangJGongLLiuGStaessenJfor the Systolic Hypertension in China (Syst-China) Collaborative GroupComparison of active treatment and placebo in older Chinese patients with isolated systolic hypertensionJ Hypertens199816182318299869017
   PubMed Web of Science ®Google Scholar
• WoodDon behalf of the EUROASPIRE III InvestigatorsRisk factor management in coronary patients-results from a Eurpoean wide survey Euroaspire III. European Society of Cardiology, 2008; Munich, Germany.
   Google Scholar
• AppelLJEspelandMAEasterLWilsonACFolmarSLacyCREffects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE)Arch Intern MedMarch 12, 20012001161568569311231700
   PubMed Web of Science ®Google Scholar
• ThijsLFagardRLijnenPStaessenJVan HoofRAmeryAA meta-analysis of outcome trials in elderly hypertensivesJ Hypertens199210110311091334990
   PubMed Web of Science ®Google Scholar
• EkbomTLindholmLOdénAA 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly peopleJ Intern Med199423565815888207364
   PubMed Web of Science ®Google Scholar
• Lund-JohansenPStopping antihypertensive drug therapy in elderly people – a dangerous experiment?J Intern Med199423565775798207363
   PubMed Web of Science ®Google Scholar
• LeverARamsayLTreatment of hypertension in the elderlyJ Hypertens19951365715797594412
   PubMed Web of Science ®Google Scholar
• LindholmLHJohannessonMCost-benefit aspects of treatment of hypertension in the elderlyBlood Pressure199545suppl 31114
   Google Scholar
• DahlöfBPreventing stroke in hypertensive patients at riskJ Am Soc Hypertens200824S3845
   Web of Science ®Google Scholar
• StaessenJMortality and treated blood pressure in patients of the European Working Party on High Blood Pressure in the ElderlyAm J Med1991903A60S61S2006663
   PubMed Web of Science ®Google Scholar
• PsatyBSmithNSiscovickDHealth outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysisJAMA199727797397459042847
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• ChalmersJCastaigneAMorganTChastangCLong-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/ diuretic combination as fist-line therapy in elderly hypertensive patientsJ Hypertens200018332733710726720
   PubMed Web of Science ®Google Scholar
• HanssonLLindholmLHEkbomTRandomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 studyLancet199935491921751175610577635
   PubMed Web of Science ®Google Scholar
• LacourcièreYA multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged ≥65 years with mild to moderate hypertensionClin Ther200022101213122411110232
   PubMed Web of Science ®Google Scholar
• The Allhat Officers and Coordinators for the Allhat Collaborative Research GroupMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA2002288232981299712479763
   PubMed Web of Science ®Google Scholar
• HanssonLHednerTLund-JohansenPRandomised trial of effects of calcium antagonists compared with diuretics and [beta]-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) studyLancet2000356922735936510972367
   PubMed Web of Science ®Google Scholar
• KjeldsenSHednerTSyvertsenJInfluence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) StudyJ Hypertens20022061231123712023696
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipinee: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipinee adding per-indopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet366948989590616154016
   PubMed Web of Science ®Google Scholar
• MoserMTreatment of hypertension in the very elderly: a clinician’s point of viewJ Clin Hypertens (Greenwich)20035531031214564130
   PubMedGoogle Scholar
• LeenenFHHNwachukuCEBlackHRClinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialHypertension200648337438416864749
   PubMed Web of Science ®Google Scholar
• LindholmLHCarlbergBSamuelssonOShould [beta] blockers remain first choice in the treatment of primary hypertension? A meta-analysisLancet36694961545155316257341
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• KjeldsenSEDahlofBDevereuxRBEffects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint Reduction (LIFE) SubstudyJAMA2002288121491149812243636
   PubMed Web of Science ®Google Scholar
• TurnbullFBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlöfBShimizuMValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet36995711431143917467513
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus Amlodipinee or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• PilzBShagdarsurenEWellnerMAliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic ratsHypertension200546356957616103264
   PubMed Web of Science ®Google Scholar
• ShagdarsurenEWellnerMBraesenJ-HComplement activation in angiotensin ii-induced organ damageCirc Res200597771672416109917
   PubMed Web of Science ®Google Scholar
• Whaley-ConnellAHabibiJCooperSAEffect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 ratAm J Physiol Endocrinol Metab20082951E10310918460596
   PubMed Web of Science ®Google Scholar
• FeldmanDLJinLXuanHEffects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 ratsHypertension200852113013618490518
   PubMed Web of Science ®Google Scholar
• GradmanAHSchmiederRELinsRLNussbergerJChiangYBedigianMPAliskiren, a novel orally effective renin inhibitor, provides ose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation200511181012101815723979
   PubMed Web of Science ®Google Scholar
• VillamilAChrysantSGBCalhounDCRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens200725121722617143194
   PubMed Web of Science ®Google Scholar
• OhB-HMitchellJHerronJRChungJKhanMKeefeDLAliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertensionJ Am Coll Cardiol200749111157116317367658
   PubMed Web of Science ®Google Scholar
• KushiroTItakuraHAboYGotouHTeraoSKeefeDLAliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertensionHypertens Res20062912997100517378372
   PubMed Web of Science ®Google Scholar
• PoolJSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens2007201112017198906
   PubMed Web of Science ®Google Scholar
• DietzRDechendRYuC-MEffects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1J Renin-Angiotensin-Aldosterone Syst20089316317518957387
   PubMed Web of Science ®Google Scholar
• JordanJEngeliSBoyeSWLe BretonSKeefeDLDirect renin inhibition with aliskiren in obese patients with arterial hypertensionHypertension20074951047105517353513
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSAPatelSFangHZhangJSatlinAEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trialLancet2007370958322122917658393
   PubMed Web of Science ®Google Scholar
• StantonAJensenCNussbergerJO’BrienEBlood pressure lowering in essential hypertension with an oral renin inhibitor, aliskirenHypertension20034261137114314597641
   PubMed Web of Science ®Google Scholar
• UresinYTaylorAAKiloCEfficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJournal of Renin-Angiotensin-Aldosterone System200784190200
   PubMed Web of Science ®Google Scholar
• AndersenKWeinbergerMHEganBComparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trialJ Hypertens200826358959918300872
   PubMed Web of Science ®Google Scholar
• DahlöfBAndersonDAroraVAliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertensionJ Clin Hypertens (Greenwich)20079suppl A93
   Google Scholar
• ParvingH-HPerssonFLewisJBLewisEJHollenbergNKthe ASIAliskiren Combined with Losartan in Type 2 Diabetes and NephropathyN Engl J Med2008358232433244618525041
   PubMed Web of Science ®Google Scholar
• McMurrayJPittBLatiniREffects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failureCirc Heart Fail200811724
   PubMed Web of Science ®Google Scholar
• SolomonSAppelbaumEManningWEffect of the direct renin inhibitor aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial Late breakeing clinical trials. American College of Cardiology 57th Scientific Sessions 2008, 2008; Chicago, USA.
   Google Scholar
• VerdecchiaPCalvoCMöckelVKeelingLSatlinASafety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertensionBlood Pressure200716638139118058456
   PubMed Web of Science ®Google Scholar
• SchmiederREPhilippeTGuerediagaJGorostideMAroraVKeefeDLong-Term aliskiren-based therapy effectively lowers systolic blood pressure and pulse pressure in elderly and very elderly patients with hypertensionHypertension 2008:22nd Scientific Meeting of the International Society of Hypertension and 18th Scientific Meeting of the European Society of Hypertension14–19 June 20082008;25.
   Google Scholar
• YarowsSOparilSPatelSFangHZhangJAliskiren and valsartan in stage 2 hypertension: Subgroup analysis of a randomized, double-blind studyAdv Ther200825121288130219066757
   PubMed Web of Science ®Google Scholar
• YarowsSAOparilSPatelSAroraVZhangJAliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in elderly and younger patients with hypertensionHypertension 2008: 22nd Scientific Meeting of the International Society of Hypertension and 18th Scientific Meeting of the European Society of Hypertension14–19 June 20082008;25.
   Google Scholar
• GradmanAHWeirMAroraVKeefeDAliskiren provides highly effective blood pressure reduction independent of age in patients with hypertension. American Society of Hypertension Annual Scienftific Meeting and Exposition, May 14–17 2000J Clin Hypertens200810Supplement A
   Google Scholar
• DuprezDADavisPBothaJAbstract 4423: The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipinee in patients ≥65 years of age with systolic hypertensionCirculation2008118 (18 Meeting Abstracts): S_886-c-887.
   Web of Science ®Google Scholar